本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 证券代码：300396 证券简称：迪瑞医疗 公告编号：2026-002 迪瑞医疗科技股份有限公司（以下简称"公司"）第六届董事会第六次临时 会议（以下简称"本次会议"）于 2026 年 01 月 30 日在公司以通讯方式召开，本 次会议由董事长郭霆先生主持，应出席公司会议的董事 9 人，实际出席公司会议 的董事 9 人，高级管理人员列席会议。根据《公司章程》的规定，本次会议通知 于 2026 年 01 月 27 日以现场及电子邮件送达方式发出，会议召开符合《中华人 民共和国公司法》、《公司章程》的规定，会议合法有效。 迪瑞医疗科技股份有限公司 第六届董事会第六次临时会议决议公告 二、会议审议情况 1、第六届董事会第六次临时会议决议； 2、深交所要求的其他文件。 特此公告。 迪瑞医疗科技股份有限公司董事会 本议案已经独立董事专门会议审议通过。 关联董事郭霆、郎涛、刘康、倪冰回避本议案表决。 表决结果：同意 5 票，反对 0 票，弃权 0 票，同意票占有效表决权 100% 三、备查文件 与会董事经认 ...

Group 1 - The core point of the article is that the general manager of China Resources Pharmaceutical Group and the chairman of Dirui Medical are the same person, Guo Ting [1] Group 2 - Dirui Medical (300396) responded to investor inquiries on an interactive platform [1]

Core Viewpoint - The company, Dirui Medical, is facing challenges in its stock performance and investor relations, with a need for clearer communication and concrete measures to improve its market position and operational efficiency [2][3]. Group 1: Stock Performance - As of January 15, 2026, Dirui Medical's stock closed at 13.61 yuan, down 1.16%, with a turnover rate of 1.21% and a trading volume of 32,800 shares, amounting to a transaction value of 44.77 million yuan [1]. - On the same day, there was a net outflow of 5.39 million yuan from institutional investors, while retail investors saw a net inflow of 4.26 million yuan [4][5]. Group 2: Investor Relations and Company Strategy - The company has a collaboration with Peking Union Medical College Hospital focused on technical research in urine and other fields, but specific progress updates are limited to periodic reports [2]. - Investors have expressed concerns regarding the company's operational strategies and the effectiveness of its various departments, suggesting a need for restructuring to enhance performance [2][3]. - There is a call for the company to take decisive actions such as share buybacks and acquisitions in advanced assets to improve its market standing and implement a dual-track operational strategy [3].

证券代码：300396 证券简称：迪瑞医疗 公告编号：2026-001 迪瑞医疗科技股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）分别于2025年09月28日、 2025年10月24日召开了第六届董事会第四次临时会议及2025年第二次临时股东 大会，审议通过了《关于变更公司经营范围的议案》《关于修订<公司章程>的议 案》等事项。具体内容详见公司于巨潮资讯网（www.cninfo.com.cn）上披露的 相关公告。 公司已于近日完成了经营范围变更相关的工商变更登记工作，并取得由长春 市市场监督管理局长春新区分局换发的《营业执照》。公司经营范围变更为： 一般项目：技术服务、技术开发、技术咨询、技术交流、技术转让、技术推 广；第一类医疗器械生产；专用设备制造（不含许可类专业设备制造）；工程和 技术研究和试验发展；第一类医疗器械销售；第二类医疗器械销售；专用化学产 品销售（不含危险化学品）；合成材料销售；电子产品销售；集成电路芯片及产 品销售；机械设备销售；纸制品销售；橡胶制品销售 ...

Group 1 - The core point of the article is that as of January 10, 2026, the number of shareholders for Dirui Medical is reported to be 16,044 [2]

Core Viewpoint - The stock price of Di Rui Medical has shown a positive trend in early 2023, with a notable increase in recent trading days, despite a significant decline in revenue and profit for the year [1][2]. Group 1: Stock Performance - As of January 12, Di Rui Medical's stock price increased by 2.08%, reaching 13.73 yuan per share, with a trading volume of 21.53 million yuan and a turnover rate of 0.58% [1]. - Year-to-date, the stock price has risen by 6.43%, with a 3.78% increase over the last five trading days, a 6.85% increase over the last 20 days, and a 1.10% increase over the last 60 days [2]. Group 2: Company Overview - Di Rui Medical Technology Co., Ltd. was established on December 26, 1994, and went public on September 10, 2014. The company is located in Changchun, Jilin Province, and specializes in the research, production, and sales of medical testing instruments and related reagents [2]. - The company's main business revenue composition includes reagents (57.13%), instruments (42.24%), and others (0.63%) [2]. - Di Rui Medical is classified under the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics [2]. Group 3: Financial Performance - As of December 31, the number of shareholders for Di Rui Medical was 15,700, a decrease of 4.99% from the previous period, with an average of 17,296 circulating shares per shareholder, an increase of 5.25% [2]. - For the period from January to September 2025, Di Rui Medical reported a revenue of 469 million yuan, a year-on-year decrease of 60.12%, and a net profit attributable to shareholders of -87.25 million yuan, a year-on-year decrease of 145.31% [2]. Group 4: Dividend and Shareholding - Di Rui Medical has distributed a total of 923 million yuan in dividends since its A-share listing, with 340 million yuan distributed over the past three years [3]. - As of September 30, 2025, the top ten circulating shareholders included a new shareholder, Dachen Jingheng Mixed A (090019), holding 1.27 million shares [3].

Group 1 - The core viewpoint of the article is that the company, DiRi Medical, has indicated that its future strategic planning information will be based on periodic reports [1] Group 2 - The company responded to investor inquiries on its interactive platform [1] - The date of the announcement was January 8 [1] - The company is listed under the stock code 300396 [1]

Group 1 - The core point of the article is that Dirui Medical (300396) has reported a total of 15,741 shareholders as of December 31, 2025 [1]

Group 1 - The core point of the article is that Dirui Medical (300396) reported a total of 15,741 shareholders as of December 31 [1]

Core Viewpoint - The company has successfully won a bid for a comprehensive laboratory solution project for key hospitals under the Ecuadorian Ministry of Public Health, marking its entry into the Ecuadorian market and showcasing the competitiveness of domestic high-end medical equipment internationally [1][2] Group 1: Project Details - The project involves the delivery of several core devices, including the CSM-8000生免流水线, FUS-3000Plus fully automated urine analysis system, BF-7200Plus fully automated modular blood fluid analysis system, and BCA-2000 fully automated coagulation analyzer [1] - The hospital is the largest comprehensive hospital in the El Oro province of Ecuador, with strict selection criteria for laboratory equipment and solutions [1] Group 2: Company Strategy and Market Position - The company emphasizes independent innovation as its core driving force, developing a product matrix and comprehensive solution system covering multiple fields of clinical testing [2] - The company has implemented a dual-drive strategy for domestic and international markets, exporting to over 120 countries and regions, and focusing on localization strategies to strengthen its international market foundation [2]